An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
The investigation reveals the role of the daily biological clock (circadian rhythms) in the regenerative capacity of skin stem cells. Disruption of this rhythm results in premature tissue ageing and a greater predisposition to the development of skin tumours. The
A team of Virginia Tech and Purdue University scientists have identified a distinct transporter used by tobacco plant cells for nicotine metabolism. The research appears in the Oct. 17 online before print issue of the Proceedings of the National Academy of Sciences (PNAS) in the article, "A tobacco nicotine uptake permease effects alkaloid metabolism."
Global Health Partner: THIRD QUARTER 2011. Revenues increased by 19 percent to SEK 129.1 million.
University of Maryland School of Medicine researchers have uncovered a previously unknown molecular pathway that is critical to understanding cardiac arrhythmia and other heart muscle problems.
Treating patients with the new blood thinning medication dabigatran (Pradaxa), instead of warfarin results in significantly higher per patient costs and higher net costs per stroke avoided, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime).The study will be presented today at the Academy of Managed Care Pharmacy's Educational Conference in Atlanta, Ga.
An iPhone app that measures the user's heart rate is not only a popular feature with consumers, but it sparked an idea for a Worcester Polytechnic Institute (WPI) researcher who is now turning smart phones, and eventually tablet devices, into sophisticated medical monitors able to capture and transmit vital physiological data.
In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.
St. Jude Medical, Inc., a global medical device company, is pleased to again participate in the Asia-Pacific Heart Rhythm Society Scientific Session (APHRS), which is being held this year in conjunction with the Japanese Heart Rhythm Society (JHRS) and the Japanese Society of Electrocardiology (JSE) in Fukuoka, Japan.
We won't stop the rising tide of infections until we develop a new business model to fight them. We are not quite on the brink of some dystopian Victorian future. But every year, the prognosis for infectious-disease patients gets a bit grimmer. … And more-powerful drugs tend to cost more than the old drugs. … Even in the rich world, death from infection still looms; MRSA alone kills thousands every year. And firms are not developing antibiotics as fast as they used to.
Many patients are responding to a new, minimally invasive way of treating irregular heartbeats by freezing out the bad cells. Atrial fibrillation (A-Fib) is one such heart rhythm disorder, and it's the most common arrhythmia affecting Americans.
Urgent coordinated action from national governments, medical societies and patient organizations is needed to avoid a public health crisis resulting from the tide of preventable strokes that leave many people with atrial fibrillation (AF) mentally and physically disabled or dead, every year. How Can We Avoid a Stroke Crisis in Latin America?, a report from Action for Stroke Prevention - a group of health experts from around the world - reveals the huge economic, social and personal burden of AF-related strokes across the region.
The heartbeat is the result of rhythmic contractions of the heart muscle, which are in turn regulated by electrical signals called action potentials. Action potentials result from the controlled flow of ions into heart muscle cells (depolarization) through channels in their membranes, and are followed by a compensating reverse ion current (repolarization), which restores the original state. If the duration of the repolarization phase is not just right, the risk of ventricular arrhythmia and sudden cardiac death increases significantly.
St. Jude Medical, Inc., a global medical device company, today announced the approval of the industry's first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds) in India. The Promote Quadra CRT-D offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.
UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.
A Swedish study presented at the ESC Congress 2011 today, found a higher incidence of arrhythmias in cross-country skiers with a long history of endurance training.
Results from the STOP-VT Study were presented at the ESC Congress 2011 today. This is the first ever multi-center, global, prospective trial to evaluate a Remote Magnetic Navigation system for the treatment of ischemic Ventricular Tachycardia.
The AF AWARE campaign today, at the European Society of Cardiology (ESC) Congress 2011 in Paris, announces the launch of the Atrial Fibrillation in Primary Care (AFIP) tool, developed to help primary care physicians (PCPs) with early diagnosis and optimal management of patients with atrial fibrillation.
New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.
Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.